ERBB2 and breast cancer: A previous study in a breast cancer mouse model, using a surrogate molecule, showed that HER2-TDB leads to increased numbers of CXCR3+ CD3+ murine T cells within the tumor [48], suggesting that this mechanism might be shared among different T cell engagers.